Neurocrine Biosciences (NASDAQ:NBIX) Sees Large Volume Increase Following Analyst Upgrade

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) saw an uptick in trading volume on Friday after Stifel Nicolaus raised their price target on the stock from $188.00 to $215.00. Stifel Nicolaus currently has a buy rating on the stock. 678,705 shares were traded during trading, a decline of 42% from the previous session’s volume of 1,176,510 shares.The stock last traded at $164.6460 and had previously closed at $185.50.

Several other brokerages also recently weighed in on NBIX. Guggenheim lifted their target price on Neurocrine Biosciences from $200.00 to $222.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings raised Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday. Royal Bank Of Canada lifted their price objective on shares of Neurocrine Biosciences from $183.00 to $195.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. HC Wainwright boosted their price objective on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. Finally, Citigroup boosted their price objective on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $197.29.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 4,367 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $181.02, for a total transaction of $790,514.34. Following the completion of the transaction, the insider directly owned 16,225 shares in the company, valued at approximately $2,937,049.50. This trade represents a 21.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $165.32, for a total value of $4,133,000.00. Following the completion of the sale, the director directly owned 15,860 shares in the company, valued at approximately $2,621,975.20. The trade was a 61.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 395,422 shares of company stock worth $62,448,693. 4.60% of the stock is currently owned by insiders.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Q2 results exceeded expectations. Neurocrine reported adjusted earnings of $2.85 per share, above the $2.26 Zacks consensus estimate, while revenue reached $959 million versus analysts’ $891 million forecast. Revenue increased approximately 39% year over year. Neurocrine Biosciences Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised full-year INGREZZA guidance. 2026 net product sales guidance for INGREZZA was increased to $2.825 billion-$2.875 billion. Second-quarter INGREZZA sales rose 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million following the Soleno Therapeutics acquisition. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Needham increased its price target. Needham & Company raised its target from $200 to $204 and maintained a “Buy” rating, signaling continued confidence in NBIX’s earnings growth and commercial outlook. Benzinga
• Neutral Sentiment: Analyst sentiment remains favorable. NBIX carries a consensus “Moderate Buy” rating and an average price target of approximately $194, although investors may be looking for additional upside after the stock’s recent strength.
• Negative Sentiment: A director sold shares. Leslie Norwalk sold 1,250 shares worth approximately $227,513, reducing her holdings by 44%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal. SEC insider transaction filing

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC increased its stake in Neurocrine Biosciences by 0.5% during the 1st quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock worth $1,721,000 after buying an additional 68 shares during the period. Huntington National Bank increased its position in shares of Neurocrine Biosciences by 12.6% during the fourth quarter. Huntington National Bank now owns 678 shares of the company’s stock worth $96,000 after acquiring an additional 76 shares during the last quarter. Perigon Wealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 3.1% in the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock worth $367,000 after acquiring an additional 78 shares in the last quarter. Motley Fool Asset Management LLC lifted its stake in shares of Neurocrine Biosciences by 4.8% in the fourth quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock worth $240,000 after acquiring an additional 78 shares in the last quarter. Finally, Main Management ETF Advisors LLC boosted its holdings in Neurocrine Biosciences by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company’s stock valued at $1,111,000 after purchasing an additional 80 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

The firm has a fifty day simple moving average of $167.61 and a 200-day simple moving average of $146.25. The company has a market capitalization of $16.70 billion, a PE ratio of 25.69, a P/E/G ratio of 0.76 and a beta of 0.39.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.